Condition 1: Delirium. Condition 2: Agitation. Delirium due to known physiological condition Restlessness and agitation
Conditions
Interventions
Intervention 1: Intervention group: The patients randomly allocated to the intervention group will receive 10mg of escitalopram daily. The escitalopram will be administered orally in the form of a tab
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age»18 years old Acute patients hospitalized in the intensive care unit (ICU under mechanical ventilation with a ventilator) Patients hospitalized in the intensive care unit without brain damage Is not currently taking any other antidepressants Not pregnant or lactating Willing to sign an informed consent form
Exclusion criteria
Exclusion criteria: Known hypersensitivity to es-citalopram or any of its components Active suicidal thoughts or behavior Severe liver or kidney failure Uncontrolled arrhythmias Active bleeding History of mania or hypomania Severe personality disorders Current substance abuse or dependence Participation in other clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Agitation. Timepoint: 3 hours after gavage of citalopram and placebo to intubated patients hospitalized in ICU for 14 days. Method of measurement: Richmond agitation sedation scale.;Delirium. Timepoint: 3 hours after gavage of citalopram and placebo to intubated patients hospitalized in ICU for 14 days. Method of measurement: CAM_ICU score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNavid Shafigh
Shahid Beheshti University of Medical Sciences
Outcome results
None listed